Dr. David T. Rubin is Chief of the Section of Gastroenterology, Hepatology & Nutrition and the Co-Director of the Digestive Diseases Center at The University of Chicago Medicine. Dr. Rubin earned a medical degree with honors at The University of Chicago Pritzker School of Medicine. He completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago, where he served as Chief Resident and Chief Fellow. Prior to his current appointments, Dr. Rubin served for 11 years as Director of the Gastroenterology, Hepatology and Nutrition fellowship program. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics and an associate investigator at the University of Chicago Comprehensive Cancer Center.
Dr. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE) and the American College of Physicians (ACP) and an active national member of the Crohn’s & Colitis Foundation (CCF), and is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), the Cancer Research Foundation Young Investigator’s Award (2004), and the UC Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the CCF Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He is currently the Chair-elect of the National Scientific Advisory Committee of the CCF. He is an Associate Editor of the journal Gastroenterology and Co-Editor of the ACG On-Line Educational Universe.
Dr. Rubin is the editor of a best-selling book on inflammatory bowel disease (IBD), now in its 3rd edition, and an author or coauthor of many peer-reviewed articles on treatment and management of IBD, cancer in IBD and novel paradigms, as well as the first author of the in progress ACG Guidelines for ulcerative colitis. His current research is in the area of progressive complications from uncontrolled inflammation, the doctor-patient relationship in IBD, and a variety of collaborative studies related to the microbiome and intestinal disease. He is also a featured media contact for issues related to IBD, appearing on satellite radio, television, print media and maintains a popular twitter feed @IBDMD (>9500 followers). His principal research interests include novel IBD therapies and outcomes, colon cancer prevention, and clinical medical ethics.
University of Chicago Pritzker School of Medicine
Chicago
Fellowship - Gastroenterology
2001
University of Chicago Pritzker School of Medicine
Chicago
Residency - Internal Medicine
1997
University of Chicago Pritzker School of Medicine
Chicago
MD
1994
University of Illinois
Urbana-Champaign
BS - Honors Biology
1990
Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device.
Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device. Inflamm Bowel Dis. 2025 Mar 03; 31(3):647-654.
PMID: 38520737
Diagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic Review.
Diagnosis of Inflammatory Bowel Disease-Associated Peripheral Arthritis: A Systematic Review. Inflamm Bowel Dis. 2025 Mar 03; 31(3):812-842.
PMID: 38836521
Increasing Exposure to Inflammatory Bowel Diseases Education in Gastroenterology Fellowship: The Pilot IBD 101 Experience.
Increasing Exposure to Inflammatory Bowel Diseases Education in Gastroenterology Fellowship: The Pilot IBD 101 Experience. Inflamm Bowel Dis. 2025 Mar 03; 31(3):746-750.
PMID: 38217539
A practical approach to positioning therapies in ulcerative colitis.
A practical approach to positioning therapies in ulcerative colitis. J Can Assoc Gastroenterol. 2025 Mar; 8(Suppl 2):S6-S14.
PMID: 39990515
The role of virtual reality in managing inflammatory bowel disease: a novel approach to bridging mental and physical health.
The role of virtual reality in managing inflammatory bowel disease: a novel approach to bridging mental and physical health. J Can Assoc Gastroenterol. 2025 Mar; 8(Suppl 2):S15-S20.
PMID: 39990506
Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study.
Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study. Inflamm Bowel Dis. 2025 02 06; 31(2):432-441.
PMID: 39093640
Intestinal Ultrasound Identified Crohn's Disease In Previously Undiagnosed Siblings.
Intestinal Ultrasound Identified Crohn's Disease In Previously Undiagnosed Siblings. Inflamm Bowel Dis. 2025 Feb 04.
PMID: 39903445
Histopathologic Evaluation and Single-Cell Spatial Transcriptomics of the Colon Reveal Cellular and Molecular Abnormalities Linked to J-Pouch Failure in Patients with Inflammatory Bowel Disease.
Histopathologic Evaluation and Single-Cell Spatial Transcriptomics of the Colon Reveal Cellular and Molecular Abnormalities Linked to J-Pouch Failure in Patients with Inflammatory Bowel Disease. bioRxiv. 2025 Jan 28.
PMID: 39974918
Multiomic analysis reveals cellular, transcriptomic and epigenetic changes in intestinal pouches of ulcerative colitis patients.
Multiomic analysis reveals cellular, transcriptomic and epigenetic changes in intestinal pouches of ulcerative colitis patients. Nat Commun. 2025 Jan 21; 16(1):904.
PMID: 39837850
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11; 19(1).
PMID: 39804294